The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Outcome of localized therapy for residual or recurrent oligo melanoma or renal cell cancer (RCC) following immune checkpoint inhibition therapy (ICI).
 
Alex Marki
No Relationships to Disclose
 
Geoffrey Gibney
Consulting or Advisory Role - Bristol-Myers Squibb; HUYA Bioscience International; Immunocore; Iovance Biotherapeutics; Lyell Immunopharma; Merck; Novartis; Pfizer; Regeneron; Replimune
Speakers' Bureau - Immunocore
Research Funding - Exelixis (Inst)
 
Kellie Gardner
No Relationships to Disclose
 
Michael Atkins
Leadership - Werewolf Therapeutics
Stock and Other Ownership Interests - Pyxis; Werewolf Pharma
Consulting or Advisory Role - 23AndMe; Abbvie; Agenus; AstraZeneca; Aveo; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Exelixis; Genentech; Innovent Biologics; IO Biotech; Jazz Pharmaceuticals; Merck; Novartis; Oncorena; Pfizer; Pliant; Pyxis; Replimune; Sanofi; Simcha Therapeutics; Syncona; Werewolf Pharma
Research Funding - Agenus (Inst); Bristol-Myers Squibb (Inst); Merck (Inst)
Travel, Accommodations, Expenses - BMS Canada; BMS Sweden